Lilly agrees to buy U.S. biotech Morphic in US$3.2 billion deal

Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about US$3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.